• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration.

作者信息

Guy-Alfandary Shiri, Zhurat Sasha, Berlin Maya, De Haan Tal, Gueta Itai, Shihmanter Renata, Golik Ahuva, Berkovitch Matitiahu, Eyal Sara, Goldstein Lee H

机构信息

Health Division, Pharmacy and Pharmacology Department, Maccabi Healthcare Services, Tel-Aviv, Israel.

Clinical Pharmacology and Toxicology Unit, Shamir Medical Center (Assaf Harofeh), Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.

出版信息

Clin Pharmacol Ther. 2022 Dec;112(6):1156-1158. doi: 10.1002/cpt.2610. Epub 2022 May 5.

DOI:10.1002/cpt.2610
PMID:35521643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9347621/
Abstract
摘要

相似文献

1
Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration.应对新冠患者中奈玛特韦/利托那韦的潜在药物相互作用：来自以色列跨部门合作的视角
Clin Pharmacol Ther. 2022 Dec;112(6):1156-1158. doi: 10.1002/cpt.2610. Epub 2022 May 5.
2
Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy.使用尼马曲韦/利托那韦治疗癫痫患者：国际抗癫痫联盟以色列分会的最新进展。
Epilepsia. 2022 May;63(5):1276-1278. doi: 10.1111/epi.17212. Epub 2022 Mar 9.
3
Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.评估与药代动力学增强剂发生药物相互作用的风险：以利托那韦增强型奈玛特韦预防重症 COVID-19 为例。
Clin Microbiol Infect. 2022 Aug;28(8):1044-1046. doi: 10.1016/j.cmi.2022.03.030. Epub 2022 Mar 28.
4
Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment.基于生理的药代动力学模型指导下口服抗凝药物在 COVID-19 治疗中起始使用奈玛特韦/利托那韦（Paxlovid）的剂量管理。
Clin Pharmacol Ther. 2022 Oct;112(4):803-807. doi: 10.1002/cpt.2687. Epub 2022 Jul 4.
5
Nirmatrelvir Plus Ritonavir: First Approval.奈玛特韦片/利托那韦片：首次获批。
Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5.
6
Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19).奈玛特韦/利托那韦治疗轻症至中症 2019 冠状病毒病（COVID-19）后的短期妊娠结局。
Obstet Gynecol. 2022 Sep 1;140(3):447-449. doi: 10.1097/AOG.0000000000004900. Epub 2022 Jun 28.
7
Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).新冠病毒感染者中奈玛特韦/利托那韦药物相互作用的管理：法国药理学和治疗学学会（SFPT）指南。
Therapie. 2022 Sep-Oct;77(5):509-521. doi: 10.1016/j.therap.2022.03.005. Epub 2022 Apr 20.
8
Nirmatrelvir-ritonavir for COVID-19.用于治疗新冠肺炎的奈玛特韦片/利托那韦片组合包装
CMAJ. 2022 Feb 14;194(6):E218. doi: 10.1503/cmaj.220081. Epub 2022 Feb 3.
9
Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.奈玛特韦和利托那韦在终末期肾病行间歇性血液透析的 COVID-19 患者中的药代动力学。
Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0122922. doi: 10.1128/aac.01229-22. Epub 2022 Oct 26.
10
Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19.采用 LC-MS/MS 同时定量检测 COVID-19 治疗患者中的奈玛特韦和利托那韦。
J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Dec 1;1212:123510. doi: 10.1016/j.jchromb.2022.123510. Epub 2022 Oct 17.

引用本文的文献

1
Pharmacokinetic Interactions of Paxlovid Involving CYP3A Enzymes and P-gp Transporter: An Overview of Clinical Data.帕罗韦德与CYP3A酶和P-糖蛋白转运体的药代动力学相互作用：临床数据概述
Curr Drug Metab. 2024;25(9):639-652. doi: 10.2174/0113892002320326250123082112.
2
CMV Retinitis in the Context of SARS-CoV-2 Infection: A Case Study and Comprehensive Review of Viral Interactions.2019冠状病毒病感染背景下的巨细胞病毒性视网膜炎：病例研究及病毒相互作用的全面综述
Pathogens. 2024 Oct 29;13(11):938. doi: 10.3390/pathogens13110938.
3
Paxlovid (Nirmatrelvir/Ritonavir)-Induced Tacrolimus Toxicity in Organ Transplant Recipients - A Review on Drug Interactions Involving CYP3A Enzymes.帕罗韦德（奈玛特韦/利托那韦）诱导器官移植受者发生他克莫司毒性——关于涉及CYP3A酶的药物相互作用的综述
Curr Drug Saf. 2025;20(3):291-302. doi: 10.2174/0115748863331165240821194206.
4
[Nirmatrelvir/ritonavir drug-drug interactions in primary care outpatients].[奈玛特韦/利托那韦在基层医疗门诊患者中的药物相互作用]
An Sist Sanit Navar. 2023 Dec 26;46(3):e1056. doi: 10.23938/ASSN.1056.